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Abstract
Background: The study sought to evaluate the impact of a Rapid Diagnostic Clinic (RDC) service designed to
improve general practitioner (GP) referral processes for patients who do not meet existing referral criteria yet
present with vague - but potentially concerning - symptoms of cancer. We sought to investigate how well the RDC
has performed in the views of local GPs and patients, and through analysis of its activity and performance in the
first two years of operation.
Methods: The study setting was a single, hospital-based RDC clinic in a University Health Board in South Wales. We
used a mixed-method process evaluation study, including routinely collected activity and diagnosis data. All GPs
were invited to participate in an online survey (34/165 responded), and a smaller group (n = 8) were interviewed
individually. Two focus groups with patients and their carers (n = 7) provided in-depth personal accounts of their
experiences.
Results: The focus groups revealed high rates of patient satisfaction with the RDC. GPs were also overwhelmingly
positive about the value of the RDC to their practice. There were 574 clinic attendances between July 2017 and
March 2019; the mean age of attendees was 68, 57% were female, and approximately 30% had three or more
vague symptoms. Of those attending, we estimated between 42 to 71 (7.3 and 12.3%) received preliminary cancer
diagnoses. Median time from GP referral to RDC appointment was 12 days; from GP referral to cancer diagnosis was
34 days. Overall, 73% of RDC patients received either a new diagnosis (suspected cancer 23.2%, non-cancer 35.9%)
or an onward referral to secondary care for further investigation with no new diagnosis (13.9%), and 27% were
referred to primary care with no new diagnosis.
Conclusions: The RDC appears to enable a good patient experience in cancer diagnosis. Patients are seen in timely
fashion, and the service is highly regarded by them, their carers, and referring GPs. Although too early to draw
conclusions about long-term patient outcomes, there are strong indications to suggest that this model of service
provision can set higher standards for a strongly patient-centred service.
Keywords: Cancer diagnosis, Early detection of cancer, General practice, Non-specific symptoms, Rapid Diagnostic
Clinic
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Background
The process of care for cancer patients, from diagnosis
to treatment, is often fragmented requiring a number of
interactions with different care professionals in primary,
secondary and tertiary care [1]. Some patients are only
identified at a late stage in the disease progression
through an emergency hospital admission, while others
may first present with first (or later) stage symptoms in
primary care. Partly in response to this variation, urgent
suspected cancer pathways for assessment of patients
with symptoms that raise suspicion of cancer in a spe-
cific site have been in place for a number of years, for
example, for suspected colorectal, lung, ovarian and
prostate cancer [2]. However, less than 40% of cancers
in Wales are diagnosed in this way, while in some places
this figure is even lower at around 35% [3]. Additionally,
many of the patients who go on to receive a diagnosis of
cancer initially present with non-specific or vague symp-
toms such as fatigue, loss of appetite or unexplained
weight loss. Although these are symptoms which war-
rant investigation [4], they do not readily align with re-
ferral criteria for many cancers when presented in
isolation and in the absence of a specific lump, bleeding
or more physically alarming symptom. In the absence of
specific pathways for this group of patients [5], unneces-
sary and unacceptable delays in diagnosis can occur [6].
As part of the Welsh Government National Cancer
Delivery Plan, two ‘Rapid Diagnostic Clinic’ (RDC) pilot
projects were established at Cwm Taf University Health
Board (UHB), and at Abertawe Bro Morgannwg UHB
(ABM; see [7] for more details). Patients with concern-
ing vague or non-specific symptoms often do not fit
existing Urgent Suspected Cancer referral criteria and,
where the underlying condition is less obvious, the gen-
eral practitioner (GP) may have to coordinate a series of
diagnostic investigations, choose a specialty to refer to,
or decide on a period of ‘watchful waiting’ to see if more
specific symptoms develop before making a referral deci-
sion. A combination of these factors can result in de-
layed cancer diagnoses, unnecessary investigations and
consultations being performed, unnecessary or pro-
longed distress for the patient [8] and, ultimately, poten-
tially poorer long-term clinical outcomes.
A single cancer pathway from primary care to Multi-
disciplinary Team (MDT) with diagnostics at an early
stage is seen as an appropriate model to use, and the
pilot RDCs have been established as a way of imple-
menting this concept. It provides a rapid access clinic
where a range of diagnostic tests are conducted on a sin-
gle visit (whenever possible), and where several special-
ists work together to speed up diagnosis for the patient.
The RDC model of care was first developed in Denmark
where research indicated that 30% of first cancer presen-
tations in general practice would be categorised as
‘vague symptoms’ [9]. This led to the development of the
RDC model where GPs could refer these types of pa-
tients for diagnostic investigations to ascertain if they
were symptomatic of cancer [10, 11]. Recent evidence
suggests that mortality among cancer patients examined
in such diagnostic centre is comparable to cancer pa-
tients diagnosed through other routes [12].
The RDC pathway targets patients presenting to their
GP with vague, ‘non-specific’ symptoms (especially fa-
tigue and weight loss, Table 1) but which nevertheless
cause the GP concern and leads them to suspect that
there might possibly be an underlying cancer diagnosis,
even in the absence of obvious cancer ‘red flags’. The
RDC provides rapid diagnoses for patients referred by
GPs with ‘vague symptoms’ which they suspect may be
indicative of cancer. In streamlining and accelerating the
cancer diagnosis process in this way it is also the
intention to capture more cancer diagnoses at an early
clinical stage.
The RDC, which was launched in stages in each of
the four UHB localities between July 2017 and Febru-
ary 2018, operates from the Diagnostic Hub within
the Royal Glamorgan Hospital. The service is open to
referrals from all Cwm Taf GP practices for patients
over the age of 18 who do not meet the criteria for
an Urgent Suspected Cancer pathway. The referral re-
lies on GP ‘gut feeling’; if the patient is experiencing
non-specific symptoms and the GP suspects an
underlying cancer diagnosis, they can be referred to
the service.
As part of the RDC referral protocol, GPs request a
suite of 11 tests (e.g. bloods, urine) and a chest X-ray at
the point of referral so results are available when the pa-
tient attends the clinic. All referrals are initially vetted
by a Consultant Physician following their receipt in sec-
ondary care to ensure they are suitable for the pathway
and do not require redirection to a site-specific pathway.
Once the test results are available on the Welsh Clinical
Portal [13], the patient is booked into the next available
RDC clinic slot by the Clinic Coordinator, with the
intention that the patient is seen within 14 days.
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Clinics are held on two separate half-days each week.
There are two parallel sessions which enable a total of
15 appointment slots each week. On arrival at the clinic,
the patient is seen by either a Consultant Physician, GP,
or Advanced Nurse Specialist where they undergo a
physical examination and medical history prior to having
a CT scan (thorax/abdomen and pelvis). The CT scan is
reported live by a Radiologist and the results and a man-
agement/ treatment plan discussed with the clinician.
The results are explained, in turn, to the patient and any
relevant onwards referrals made. At this point the pa-
tient is discharged from the RDC service. The entire
clinic appointment lasts approximately 2 h and there are
three main outcomes: suspected cancer (with a referral
to the cancer MDT, or for further investigation); a non-
cancer diagnosis (with a referral to an appropriate sec-
ondary care clinic, or back to GP); or nothing specific is
diagnosed (usually referred back to GP, although a sec-
ondary care referral for further tests is also possible).
The multi-disciplinary RDC team is led by a consult-
ant respiratory physician and at the time of the study in-
cluded the following team members:
 Consultant physicians (2)
 Radiologist (3)
 Advanced Nurse Practitioner (1)
 GPs (3)
 Clinic Coordinator (2)
 Healthcare Support Worker (1)
 Management support (provided by the Radiology
Directorate and Planning Department)
Our study was driven by two main questions:
1. How well has the RDC performed in the views of
local GPs and patients?
2. What has the activity and performance of the RDC
been in the first 2 years of its operation?
Methods
All analyses were carried out on data and boundaries as-
sociated with Cwm Taf UHB prior to 1 April 2019
(when it became Cwm Taf Morgannwg). Unless other-
wise stated, analyses are based on data up to 31st March
2019.
Patient engagement focus groups
Two focus groups were held with patients and their sup-
porters (usually close family members) where all de-
scribed their experiences of the RDC in depth. This
included the background to their condition, and their
care and support journey from initial treatment of symp-
toms in primary care through to RDC referral. The pa-
tients were approached by RDC managers to take part if
they so wished. Each focus group was facilitated by the
two authors with a Cwm Taf staff member also in at-
tendance and lasted about 90 min.
GP engagement
As GPs are the sole point of referral to RDC, their use
and experience of it as an effective clinical service is cru-
cial to its success and it was essential to obtain their
views on this. We approached this in two ways:
 Through an online questionnaire sent via Practice
Managers giving all Cwm Taf GPs an opportunity to
respond.
 A more detailed evaluation via a series of one-to-
one, semi-structured interviews with selected GPs
(conducted by the authors).
The online survey comprised multiple-choice ques-
tions taking about 10 min to complete and with op-
tions to comment further for each - and many did so.
Stratification of the interview sample reflected a range
of practice sizes, location, and frequency of RDC
referrals.
Each face-to-face interview was conducted by both or
one of the two male co-authors with experience in con-
ducting qualitative interviews and lasted between 30 and
45min. Participants were approached via telephone and/
or email and the interviews took place in their practices
(apart from one that took place in a public space). De-
tailed notes were taken during the interviews, which
were not audio or video recorded, and no one else was
present besides the participants and the researchers.
This provided an informal atmosphere for discussion
without unduly compromising the quality of the infor-
mation obtained [14]. Interview notes were sent to the
interviewees via email to solicit their comments and
feedback. Prior to the interviews, neither of the authors
was known to the participants and therefore they had no
pre-existing relationship with them. Participants were in-
formed about the study both verbally and in writing
using a participant information sheet. No characteristics
about either of the interviewers were reported. Both the
questionnaire and interview guide, which was developed
for this study and was pilot tested in the first interview,
can be found in the supplementary file. A hybrid ap-
proach to thematic analysis was used, whereby themes
were identified directly from the data (inductively), and
by considering the aims of evaluation (deductively) [15].
Data analysis was carried out by both researchers.
Routinely collected data
We used several anonymised datasets provided by the
Cwm Taf UHB information team. Specifically:
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1. An electronic dataset, maintained within the RDC,
of all patient referrals received from inception until
31st March 2019. This included all patients who
attended the clinic as well as those whose referral
had been received although they may not have
attended before 31st March). Also included were
referrals clinically reviewed in the RDC but deemed
not necessary to attend. Data recorded in this
dataset includes basic patient demographic
information (age, gender), referral and appointment
dates, specialist seen, patient diagnoses and
outcomes (in terms of further referrals).
2. Routinely collected hospital activity data for those
patients known to have had an RDC appointment
between 1 July 2017 and 31 March 2019 (i.e. from
the inception of the RDC to the end date of the
evaluation period). These included all patient
referrals to the clinic who attended, as well as those
who were invited, but did not attend (e.g., due to
personal reasons or hospital cancellation) and for
whom we could not find a subsequently re-
arranged and attended RDC appointment. This
dataset did not include referrals that were reviewed
but not invited to attend the RDC clinic.
3. Routinely collected hospital data for cancer patients
from the Cancer Network Information System
Cymru (CaNISC) which is a national cancer patient
tracking system for Wales.
Significant effort was required in data preparation
prior to analysis which included: cross-referencing re-
cords across the different datasets; accounting for dupli-
cate records (some represented multiple RDC
attendances by the same patient); accounting for mis-
typed hospital numbers (crucial to linking data items
across different activity data sets); referral and treatment
dates not correctly connected with appointment dates.
We also supported local codification of free-text data
fields in the local RDC dataset to enable quantitative
analysis.
The linked evaluation dataset was used to conduct de-
scriptive statistical analysis (mean, standard deviation,
proportion, median, and interquartile range) and to cal-
culate the following metrics: preliminary cancer diagno-
sis rate (the number of patient with a cancer diagnosis
over the number of patients attending the RDC; some-
times referred to as the cancer conversion rate); the me-
dian times and interquartile range (IQR) from GP
referral RDC appointment and from GP referral to can-
cer diagnosis.
Costs
Given the documented challenges with conducting cost
effectiveness analysis in this setting [16] and as the RDC
was already in operation when our study commenced,
we adopted a pragmatic design focusing on direct RDC
fixed staff costs averaged over first attendances, and
marginal treatment costs related to the number of pa-
tient first attendances. As we were limited to routinely
available data, these figures are illustrative rather than
definitive as they do not, for example, include manage-
ment or estate overhead costs.
Results
Patient engagement
We organised and facilitated two patient focus groups
attended by seven participants in total; patients (n = 4)
accompanied by partners or relatives (n = 3). Both
groups were ‘very satisfied’ with their experiences of the
RDC process and the sensitive manner with which po-
tentially very difficult results and information were pre-
sented. There was sufficient time for clear explanations
about the implications of the diagnosis, and direct in-
volvement of patient supporters/ carers throughout. The
speed of the referral process was particularly highly val-
ued as it lessened ‘worry time’ for patients and carers.
All said they had no hesitation in recommending the
RDC to any friends or family with similar symptomatic
conditions to proactively seek a referral to the RDC ser-
vice (and one had actively done so). Specific suggestions
for further improvements were offered including:
 Ensuring good communication channels between
GPs, the RDC and other hospital departments
 More information about the RDC for patients at GP
practices
 Additional RDC clinic sessions to enable more
patients to benefit from the service
Case study vignette – patient A
– An active adult, this person had noticed getting tired
and short of breath in September 2018 with fatigue
and weight loss (more than 2 kg in 1 month) as
principle symptoms.
– After a further recurrence of fatigue, they attended
their GP in February 2019. Blood tests and an X-ray
were inconclusive but, after returning to their GP in
March 2019 with similar symptoms, they were re-
ferred to the RDC which they attended in April
2019. The overall experience was positive, reassuring
and efficient from point of arrival. After initial body
measurements they were examined by a doctor and
had a CT scan where the radiographers explained
everything clearly.
– After a short break, they returned to the clinic to be
given a ‘no cancer’ diagnosis, but ‘background
emphysema’ and gallstones were reported and a
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referral for ultrasound was made at that time (at the
time of interview, this follow-up was still awaited).
Despite still having some symptoms, there was relief
at having a likely diagnosis and having results on the
same day was very important for them.
Case study vignette – patient B
– This adult had recurring urinary tract infections
over a 3 month period in early 2018 which did not
respond to antibiotics. Their GP suggested referral
to the RDC, which was attended 10 days later in
early summer 2018 following all pre-clinic prelimin-
ary tests.
– They had an ‘excellent explanation’ by the clinician
on the initial consultation at the clinic about what to
expect and, following the CT scan, received a
diagnosis of a likely non-Hodgkin’s lymphoma can-
cer at the end of the afternoon. They felt that there
was plenty of time given to explain what that meant
for themselves and their spouse, with good reassur-
ance as to the potential for treatment and that there
was no cause for panic.
– A follow-up PET scan also revealed a small malig-
nant growth in the lung; six courses of chemo later
and they feel ‘mainly OK’ now.
– Both the patient and their spouse attribute a large
part of this success from the reassurance given, and
from knowing the nature and extent of the
condition in a very short time rather than weeks of
waiting.
– “I don’t think I would have been diagnosed and
treated so quickly if that clinic didn’t exist”. “It saved
my life”.
GP engagement
We undertook two forms of GP engagement: direct in-
terviews with eight GPs on their experience of referring
patients to the RDC, and an online survey sent to all GP
practices which was completed by 34 /165 GPs (21%),
with 11 out of 34 respondents (32%) also providing valu-
able supplementary commentary. Practices from all
UHB localities responded to the survey.
Online survey results indicated that GPs were over-
whelmingly positive about the RDC with 88% of respon-
dents either satisfied or very satisfied, and often coupled
with strongly supportive additional comments (‘I think
this clinic has made a big difference to my practice’).
Aspects of the RDC service (such as clarity of referral
criteria; ease of the referral process; speed with which
patients were seen; quality of information fed back to
GPs) were also highly rated (typically 80–90% of respon-
dents were ‘satisfied’ or ‘very satisfied’). However, certain
aspects were less positively viewed: 18% of respondents
reporting that there were ‘very often’ problems or signifi-
cant delays in ordering pre-RDC attendance tests (diffi-
culties in the specimen collection service from practices
were mentioned by several respondents, for example, a
practice did not have access to a daily transportation ser-
vice of samples to a laboratory).
An interesting finding concerned levels of ‘RDC
awareness’ within primary care. Among GP principals
this was ‘high’ or ‘very high’ (94%), dropping to 59% for
trainees, and only 10% for locums.
Results from the GP interviews also demonstrated
overwhelming support for the RDC and the value it pro-
vided for clinicians and patients. Benefits frequently
mentioned included:
 Speed of referral and diagnosis
 Ease of access for diagnostic testing (especially CT
scans)
 Straightforward referral process
 Reduction of stress for GPs in being able to refer
patients for vague symptoms.
The last point was particularly notable. GPs were not
only concerned about delays in diagnosis and back-and-
forth referral and testing for their patients, but also at
the ‘loss of professional face’ they sometimes previously
experienced when they had referred a patient with vague
symptoms only to have them rejected as an inappropri-
ate referral to that particular specialty. With the RDC
that potential stigma is removed.
Rapid access to diagnostic testing was seen as par-
ticularly helpful. However, issues were mentioned over
having pre-appointment tests undertaken in time (by
the GP), and the report-back process also came in for
some negative comment. However, we understand an-
ecdotally that this can be due to the way in which re-
ports are managed within practices themselves rather
than the speed of reporting back to them from the
RDC itself.
Specific recommendations about the RDC made by
GPs included:
1. Continuous promotion of awareness of the RDC,
especially to support locums and trainees.
2. Introduce more feedback to primary care about
RDC performance such as waiting times and
outcomes.
3. Introduce pre-printed haematology and microbiol-
ogy blood forms specifically for RDC referral tests
and develop an electronic referral form accessible
from GP systems with reminders about tests that
could be auto-populated with patient details.
4. Consider extending the clinic for the rapid
diagnosis from suspected cancer to other diseases
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and conditions (e.g. pulmonary fibrosis or
abdominal pain).
5. Review the requirement for pre-RDC tests for
patients.
Process and outcome evaluation of RDC activity
Between July 2017 and 31st March 2019, 681 referrals
resulted in 574 (84%) attendances (the introduction of
the RDC was staggered across four localities; starting
with Cynon in July 2017 and finishing with Taf Ely in
February 2018), Table 2. There were 4 hospital cancella-
tions, 6 patient cancellations, 3 patients who did not at-
tend their appointment, and 94 referrals that were either
not required to attend (as deemed by the senior RDC
clinician) or had been referred, but were yet to receive,
an RDC appointment.
Of those attending an RDC appointment, the average
age was 68 (68.3 for women; 67.6 for men); 58% were fe-
male; and approximately 30% had three or more vague
symptoms, Table 3. The mean number of symptoms re-
corded by the referring GP dropped from 2.83 at the
start of the operation of the RDC, to 1.53 symptoms in
Quarter 1, 2019. ‘Weight loss’ was by far the most com-
mon symptom and there was a strong association be-
tween that and ‘lack of appetite’ with 100 patients
presenting with both symptoms.
The local RDC database contains outcomes following
the patient visit, Table 4. Of those, 59 patients (10.3%)
were referred onwards to a specialist cancer pathway
(directly to the Multi-Disciplinary Team meeting stage),
and an additional 74 patients (12.9%) had a suspected
cancer with further investigations deemed necessary. Al-
most a quarter of patients (128, 22.3%) were given a
new, non-cancer diagnosis and referred to specialists in
secondary care for further review and treatment. A fur-
ther 78 patients (13.6%) received a new, non-cancer
diagnosis but were referred back to their GP for evalu-
ation and treatment. The remainder received no new
Table 2 Patients referred to the Rapid Diagnostic Clinic (RDC)
between 1st July 2017 and 31st March 2019
Patients referred to RDC
(N = 681)
All referrals, n (%)
Attended 574 (84.3)
Hospital cancellation 4 (0.6)
Patient cancellation 6 (0.9)
Patient did not attend (DNA) 3 (0.4)
Appointment not offered 94 (13.8)
Appointment not offered, n (%) [N = 94]
Awaiting scheduling of appointment 26 (27.7)
Admitted to hospital 15 (16.0)
Referred to other cancer pathway 14 (14.9)
Referred to other non-cancer pathway 14 (14.9)
Referred back to GP 10 (10.6)
Patient declined/could not be contacted 7 (7.4)
Other/unknown 5 (5.3)
Deceased 3 (3.2)
Table 3 Patients attending the Rapid Diagnostic Clinic (RDC):
demographics and referral symptoms
Demographics Patients attending RDC
(N = 574)
Age at appointment
Mean (SD) 68.0 (14.2)











Symptom type, n (%) [N = 1198]
Weight loss 438 (36.6)
Fatigue 153 (12.8)
Lack of appetite 113 (9.4)
Unexpected lab result 80 (6.7)
Abdominal pain 74 (6.2)
Nausea 60 (5.0)
Anaemia 55 (4.6)
Shortness of breath 30 (2.5)
Other 195 (16.3)
RDC Rapid Diagnostic Clinic, SD Standard Deviation, IQR Interquartile Range
Table 4 Recorded outcomes of patients attending the Rapid
Diagnostic Clinic (RDC)
Outcomes n %
A1 - Suspected Cancer (to MDT) 59 10.3
A2 - Suspected Cancer (further investigations) 74 12.9
B1 - Non-cancer diagnosis (to secondary care) 128 22.3
B2 - Non-cancer diagnosis (back to GP) 78 13.6
C1 - No new diagnosis (to secondary care) 80 13.9
C2 - No new diagnosis (back to GP) 155 27.0
Total 574 100.0
MDT Multi-Disciplinary Team, GP General Practitioner
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diagnosis and were either referred to secondary care (80,
13.9%), or back to their GP (155, 27%).
For the purposes of this evaluation we assumed that
all ‘A1’ outcomes indicated a cancer diagnosis (n = 59)
and a brief review of additional information highlighted
at least 12/ 74 of the ‘A2’ outcomes as also potentially
indicative of cancer, giving an estimated total of 71 pa-
tients seen at the RDC with a strong suspicion of cancer
(with all cancer diagnoses subject to confirmation by
biopsy).
We also analysed an extract of routinely collected hos-
pital data for cancer patients which is compiled at an all-
Wales level (CaNISC; see routinely collected datasets in
the Methods section and glossary). As there is a time lag
before patient records appear in this database, we did
not expect to obtain all confirmed cancer diagnoses fol-
lowing an RDC appointment, but we were able to iden-
tify 42 patients with a confirmed cancer diagnosis
following their RDC clinic attendance.
Based on the above data, two different preliminary
cancer diagnosis rates were calculated: 7.3% (42/574)
and 12.3% (71/574), which represent the likely lower and
upper bounds of the RDC ‘cancer diagnosis’ rate.
Using the CaNISC data for the 42 confirmed cases, we
identified the tumour site for these patients as well as
the treatment they received (Table 5). Gastro-
oesophageal cancers were the largest group (21%),
followed by urological and lung cancers (both 17%), and
colorectal and haematological cancers (12% each).
A key RDC objective is to identify non-cancer diagno-
ses (B1 and B2) as well as cancers in patients referred
with vague symptoms. Overall, 73% of patients seen re-
ceived either a diagnosis (cancer or non-cancer) and/or
an onward referral to secondary care, (i.e. all outcomes
except C2).
A record of subsequent non-cancer diagnoses is not
maintained, but we undertook a classification of the type
of condition based on a text field analysis of the diagno-
sis and specialty of onward referral where known (Fig. 1).
Respiratory (n = 46 onward referrals) and GI-related re-
ferrals (n = 42) were the most common (whether to sec-
ondary care or GP). Several classified as ‘mental health’
(n = 6) relate to drug and alcohol addiction; these were
all referred back to the GP. Conversely, cardiac referrals
(n = 11) are nearly all to secondary care. Endocrinology
(n = 12) includes several patients where their diabetes
appeared to be out of control. Several referrals appear to
be for (potentially) two different types of diagnosis.
Finally, median time to RDC appointment from GP
referral was 12 days (IQR 7, 19) and median time
from GP referral to cancer diagnosis was 34 days
(IQR 13, 50).
Costs
There are two main cost dimensions: fixed (e.g. staff)
and marginal (e.g. scans, tests). Fixed costs do not vary
in the short to medium term and their unit cost thus de-
creases as increasing numbers of patients are seen within
the available capacity (15 patients per week over two ses-
sions on a Tuesday afternoon and a Thursday morning).
Additional capacity would require a step-change increase
in fixed costs for more clinic sessions and staff time.
Marginal unit costs, however, increase directly with the
number of patients seen with every extra patient gener-
ating additional expenditure.
Patients attend the clinic for 2–3 h altogether, at least
1–2 h of which is time waiting between the initial con-
sultation and scan for the results and follow-up final
consultation and diagnosis. From relevant 2018/19 cost
outturn data we derived a staff cost per first attendance
of each patient (£321). This includes all direct clinical
and non-clinical staff time ascribed to the RDC (which
includes consultant radiology and RDC clinicians). We
were also provided with marginal cost data associated
with undertaking blood tests and radiology examinations
in the hospital (£185 per patient first attendance). All
patients undergo the same suite of investigations irre-
spective of clinical presentation. However, we were not
able to obtain any RDC clinic overhead costs, so our es-
timated total cost per first patient attendance – £506 –
is an under-estimate.
Table 5 Primary tumour site and types of treatment for Rapid
Diagnostic Clinic (RDC) patients diagnosed with cancer (N = 42)











Palliative care 13 31.0
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Discussions
Summary of findings
In this paper, we report on a process evaluation study
that explored the initial impact of a new RDC referral
pathway on patient and staff experience and on process
outcomes using a mixed-method, pragmatic study de-
sign. More and earlier stage cancer detection and im-
proved long-term survival rates are key objectives of the
RDC model. Although these objectives could not be
evaluated per se, our study found that the RDC pathway
enables a good patient experience in cancer diagnosis.
Patients are seen quickly and the pathway is highly
regarded by them, their supporters, and referring GPs.
Using the seven ‘service implementation’ outcomes of
feasibility, fidelity, penetration, acceptability, sustainabil-
ity, uptake and costs described by Proctor et al. [17], the
RDC implementation studied here has demonstrated to
be a feasible service having been successfully rolled-out
across four localities in seven months to include all GP
practices. Available clinic slots are all routinely occupied;
and we found high awareness and support among GPs
about the service. Its take-up is evenly spread across the
four UHB localities. Service referral protocols are
followed and, where necessary, have been adapted fol-
lowing constructive engagement with primary care. Pa-
tients, too, have been supportive in their experience of
the clinic as the focus groups showed. Regarding costs,
although we were only able to undertake a limited ana-
lysis of RDC-specific costs, these were acknowledged to
be commensurate with existing local clinic costs and
were comparable with findings from the Swansea pilot
study [7]. Unfortunately, there were no cost data avail-
able to compare with similar RDC-type clinics in
England.
Comparison with existing literature/ studies
A number of similar initiatives have been launched in
the UK, Table 6. In London, Guy’s and St Thomas’s
NHS Trust (GSTT) was an early adopter of the RDC in
the UK. Together with Oxford, this is a Cwm Taf com-
parator site (discussed below). In England, Cancer Re-
search UK and Macmillan established the Accelerate,
Co-ordinate, Evaluate (ACE) Programme of 50 sites
trialling an RDC approach focused on cancer detection
and diagnosis [18]. A second phase – ACE 2 (or ACE-
MDC) – ran in five sites (including Oxford) which in-
cluded non-cancer diagnoses [19].
Initial findings from ACE-MDC [20] indicate similar
achievements to Cwm Taf, and similar difficulties in
obtaining cancer staging data (noting many cancers only
first presenting at an advanced stage, and it is too early
to assess if there has been any significant increase in
earlier stage diagnoses). In Oxford, for example, only
51% of diagnoses had cancer staging data available, and
61% of patients first presented at a late stage.
Parallels with Cwm Taf are also seen with the Rapid
Access Diagnostic Clinic (RADC) clinic at GSTT. This
clinic has a larger throughput (30–40 per week), and
also accepts direct A&E and GI specialty referrals as well
as from GPs. They report (unpublished internal report)
51% of patients had attended their GP more than three
times before referral; 48% of patients reported experien-
cing symptoms for 2–6 months and 38% more than 6
months.
Patient satisfaction was high both in Oxford (70%) and
GSTT (91%) as was that of GPs (Oxford 90%; GSTT
84%).
An important caveat is that although the metrics pre-
sented are similarly described, there was insufficient
Fig. 1 RDC patients with non-cancer onward referrals by ‘diagnosis group’ (n = 206). Blank: no diagnosis recorded in the dataset
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information to ascertain exactly how data were recorded
(e.g. definition of eligible RDC population), or how some
measures were calculated locally (e.g. recording time
period).
In comparison to site-specific cancer pathways, our es-
timate of cancer diagnosis rate is in line with estimates
in national studies that reported median rates between 8
and 17.0% across a number of urgent suspected cancer
pathways.
The other Wales RDC pilot project at Abertawe Bro
Morgannwg UHB began a few months earlier than Cwm
Taf and was evaluated after a similar length of time of
operation. A very different evaluation approach was
adopted here using discrete-event simulation to model a
cohort of 1000 patients from referral to radiological
diagnosis based on routine RDC and hospital data [7].
These were compared with a control cohort of patients
who had been referred to an Urgent Suspected Cancer
pathway but subsequently downgraded. Their conclusion
was that the RDC for patients presenting with vague or
non-specific symptoms suspicious of cancer in primary
care reduces the time to diagnosis and provides excellent
value for money if run at ≥80% capacity with at least five
patients per clinic (£646 per patient). There are currently
no comparable cost data available from the ACE-MDC
sites in England.
Limitations
There are several limitations associated with this study.
As our data collection and analysis was situated in a sin-
gle organisation, we do not know whether our findings
and conclusions can be generalised in different settings.
However, given that many of our findings are in line
with studies using different methodologies in different
settings, we are confident that the lessons learnt here
have a wider applicability. The lack of a control or com-
parator group of patients limits the conclusions that can
be drawn from our study which is a similar issue faced
by all other studies that have evaluated comparable new
clinic designs. The nature of the study design also limits
our capacity to analyse the outcomes of those patients
who were diagnosed with cancer, as does the incomplete
data on cancer staging (and which we thus we did not
report on). Although we made an effort to interview GPs
from practices with a range of referral activity and loca-
tions (and solicited the opinion of all GPs through the
survey), participant bias may be present in the sample of
GPs who responded and in the patients who participated
in the two focus groups.
Implications for further research
In line with previous studies, it was a challenge to iden-
tify and use a control group for comparison purposes.
Future research and evaluation methods can contribute
to the evidence base by overcoming this challenge, for
example by using a ‘difference-in-differences’ study de-
sign [21]. Long-term patient outcomes are unknown and
future studies should make an effort to address including
long-term cancer survival, and types and outcomes of
patients receiving non-cancer diagnoses. Further re-
search is also needed to estimate the costs and benefit
implications of extending the RDC model to additional
cancer diagnostic pathways.
Implications for practice
A number of practical recommendations for the RDC
service were made during the course of the study arising
from observations by the research team as well as from
recommendations made by GPs (interviews and survey)
and patients (focus groups). These can be grouped under
three sub-headings:
Suggestions from patients and supporters
 Further improve liaison and communication with
GPs and other hospital departments in terms of
passing information back to patients.
 Clarify and formalise the summary of the diagnosis
for the patient.
 Expand RDC provision to benefit larger numbers of
patients.
Suggestions from GPs
 Improve awareness of the RDC to GPs through a
variety of means including:
Table 6 Cwm Taf in comparison with other sites that have implemented a version of the Rapid Diagnostic Clinic
Cwm Taf ACE-MDC Oxford SCAN GSTT RADC
Cancer diagnosis rate 7.3–12.3% 8% overall
(4–11% within sites)
10% 7%
Time to RDC appointment (days) Mean 13.9
Median 12
Median 8 – Mean 10.2
Time to start of cancer treatment (days) Mean 40
Median 34
Median 19 27a Mean 43
ACE-MDC Accelerate, Co-ordinate, Evaluate Multidisciplinary Diagnostic Centres, Oxford SCAN Oxford Suspected CANcer pathway, GSTT RADC Guy’s and St
Thomas’s NHS Foundation Trust Rapid Access Diagnostic Clinic
a Unclear whether this figure is for a median or mean number
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– orientation packs for locums and GP trainees,
and presentations in the local half-day release
training scheme (note, trainees do not practice in
the RDC)
– provision of RDC patient case study vignettes as
examples
– the introduction of a liaison session about the
RDC every 6 months for new cohorts of trainee
GPs
 Introduce frequent feedback to primary care on
RDC performance such as waiting times and
outcomes.
 Introduce a simple electronic referral form,
accessible from the GP system, with reminders
about tests and that could be auto-populated with
patient details (as currently happens with other hos-
pital referrals).
 Extend the clinic for the rapid diagnosis of different
diseases (e.g. pulmonary fibrosis or abdominal pain).
Suggestions from the evaluation team
 Improve the routine collection, timeliness and
quality of data to enable greater ease of
reconciliation between the different datasets and
more up to date information on cancer diagnoses
and their staging.
 Introduce, as part of routine practice, a generic
multi-attribute instrument for measuring health sta-
tus (such as EQ-5D, in line with NICE guidance).
 Undertake a detailed cost analysis at the local Health
Board level between selected RDC and existing USC
pathways and other, non-cancer pathways.
Conclusions
Although it is still too early to draw firm conclusions
about long-term cancer survival rates (and cancer sta-
ging data are not sufficiently timely or robust to enable
conclusions as to indicate any increase in early-stage de-
tection rates), there are positive indicators to suggest
that this model of service provision – popular with both
patients and clinicians – can set new and higher stan-
dards for joint primary and secondary cancer care work-
ing and provide a patient-centred care service.
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